VANCOUVER, British Columbia, May 07, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company, today announced that the company will present at the 2024 RBC Capital Markets Global Healthcare Conference taking place May 14-15, 2024 in New York, NY.
| Fireside Chat Presentation Details: | |
| Date: | Tuesday, May 14, 2024 |
| Time: | 3:35 pm Eastern Time |
| Webcast: | Register here |
| Presenters: | Ian Mortimer, President and Chief Executive Officer Sherry Aulin, Chief Financial Officer |
A live webcast of the company presentation will be available on the “Investors” section of Xenon's website and posted for replay following the event. The above listed dates and times are subject to change.
About Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals (Nasdaq:XENE) is a neuroscience-focused biopharmaceutical company committed to discovering, developing, and commercializing innovative therapeutics to improve the lives of people living with neurological and psychiatric disorders. We are advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. For more information, please visit www.xenon-pharma.com.
“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.
Contacts:
For Investors:
Chad Fugere
Vice President, Investor Relations
(857) 675-7275
This email address is being protected from spambots. You need JavaScript enabled to view it.
For Media:
Jodi Regts
Xenon Corporate Affairs
(604) 484-3353
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$38.07 |
| Daily Change: | -0.97 -2.48 |
| Daily Volume: | 481,366 |
| Market Cap: | US$2.870B |
May 09, 2024 April 16, 2024 April 10, 2024 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
